Linsitinib-d3
Added to RFQ
For Research & Analytical Purposes. Not for Personal use.
Packaging & Handling
Indicative product packaging is shown for visual reference. Actual packaging may vary based on pack size, quantity, storage condition and shipping requirements.
Documentation Available
Detailed specifications, certificates, and supporting documents are available upon request.
Detailed specifications, certificates, and supporting documents are available upon request.
Storage: Refer MSDS for complete information.
Hazard: Refer MSDS for complete information.
Linsitinib-d3 Product Information
Linsitinib-d3 is listed under Stable Isotopes and is intended for analytical research, quality control and pharmaceutical reference standard applications. The product is supplied by Clearsynth under CAT No. CS-T-98818.
Clearsynth provides this compound for research and analytical use, with product information including CAS number, molecular formula, molecular weight and product enquiry details.
Technical Data
Product Name
Linsitinib-d3
CAT No.
CS-T-98818
HSN Code
38229010
Country of Origin
Can be shipped from India, Canada and USA
Molecular Formula
C26H20D3N5O
Molecular Weight
424.51
Category
Storage Condition
Refer MSDS for complete information.
Hazard Compound
Refer MSDS for complete information.
Description
Regulatory Description
Linsitinib-d3 is supplied with detailed characterization data compliant with regulatory guideline. Linsitinib-d3 can be used for analytical method development, method validation (AMV), Quality Control (QC), ANDA-related analytical work, and commercial pharmaceutical research applications.
Overview
"Labelled Linsitinib (L469020). Linsitinib is a small-molecule dual insulin-like growth factor-1 receptor (IGF-IR) and insulin receptor (IR) kinase inhibitor. IGF-I receptor (IGF-IR) has been implicated in the promotion of tumorigenesis, metastasis and resistance to cancer therapies and thus Linsitinib may be a useful anticancer agent."
Synonyms
Linsitinib-d3
Application Notes
"Labelled Linsitinib (L469020). Linsitinib is a small-molecule dual insulin-like growth factor-1 receptor (IGF-IR) and insulin receptor (IR) kinase inhibitor. IGF-I receptor (IGF-IR) has been implicated in the promotion of tumorigenesis, metastasis and resistance to cancer therapies and thus Linsitinib may be a useful anticancer agent."
Product Applications & Regulatory Search Terms
Useful product, supplier and regulatory search terms for this reference standard.